Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is an international biopharmaceutical company that drives the research and development of novel fully human antibody-based drugs using innovative technologies.  Biocytogen is committed to technological innovation to become a global birthplace of novel drugs to safeguard human health.

Founded in June 2016, China Life Private Equity Investment Co., Ltd. is a specialized private equity investment platform and a subsidiary of China Life. In 2016, the company launched the China Life Healthcare Fund, which is a leading flagship fund in China’s healthcare industry, and the first approved private equity fund sponsored by insurance capital following the issuance of relevant policies by China Insurance Regulatory Commission.

PICC Capital Insurance Asset Management Co., Ltd. is a wholly owned subsidiary of The People's Insurance Company (Group) Of China Limited (601319.SH, 1339.HK). The company invests in a wide range of sectors such as energy resources, infrastructure, science and technology innovation, and healthcare to generate long-term returns for institutional investors.

Founded in 2016, SDIC Venture Capital Co., Ltd. (SDIC Venture Capital) is a fund management company independently managed by the State Development and Investment Corp. under a market-based governance structure. Currently, the company manages assets valued at a total of RMB 22 billion. With the aim of “serving the national innovation strategy and focusing on the transformation of scientific and technological achievements”, SDIC Venture Capital carefully balances its goals of policy orientation and return on investment in its innovative practice of exploring the industrialization of scientific and technological achievements, thus effectively implementing the national development strategy while achieving a win-win situation for the government, society, and the market.

Oriza Holdings is a state-owned investment holding company controlled by Suzhou Industrial Park Administrative Committee with equity participation from Jiangsu Guoxin Group. Its business covers three major sectors: equity investment, debt financing, and investment and financing services. Among them, equity investment is the most important business segment for Oriza Holdings. After years of focused and in-depth development in this segment, the company has grown into a first-class equity investment institution in China, with a current managed fund size of over RMB 100 billion.

Suzhou Harvi Capital Management Co.,Ltd. (Harvi Capital) is a fund management company approved by the Party Working Committee and the Management Committee of Suzhou Industrial Park. Harvi Capital manages a total fund size of RMB 12 billion, including 10 billion of government-led industry-oriented funds and 2 billion of angel master funds. The Harvi Capital team comprises of members hailing from well-known domestic institutions, with strong industrial background and rich investment experience. Through direct investment and master fund investment, Harvi Capital gives full play to the driving role of industrial guidance funds and angel master funds, promotes the implementation and development of projects in the key industrial directions of the park, and help accelerate the construction of a world-class high-tech industrial park.

Established in December 2012, Suzhou Industrial Park Lingjun Venture Capital Co., Ltd. (Lingjun Venture Capital) is an angel investment company approved by Suzhou Industrial Park Administrative Committee, and is 100% owned by Suzhou Industrial Park Enterprise Development Service Center. With a registered capital of RMB 307.5 million, Lingjun Venture Capital mainly invests in early-stage technology-based projects with a focus on emerging industries such as artificial intelligence, healthcare, and nanotechnology applications, to accelerate the growth of enterprises and facilitate government-led science and technology innovation.

Taiping Healthcare Industry Equity Investment Fund is managed by Taiping Innovation Investment, a private equity firm under China Taiping Insurance Group. Taiping Healthcare Fund has successfully registered with the Insurance Asset Management Association of China and the Asset Management Association of China. The fund has a registered size of RMB 10 billion, of which RMB 5 billion has been contributed by Taiping Life Insurance. The fund will adopt a combination of direct and indirect investment strategies, focusing on sectors including biopharmaceuticals and pharmaceutical outsourcing, medical devices and diagnostics, medical services, biotechnology and medical information technology, radiological health technology and healthcare expenditure.

China Merchants International Finance Co., LTD (CMB International) is a comprehensive, professional, and integrated financial service provider based in Hong Kong, with strong roots in the Mainland and a global perspective, and is a wholly-owned subsidiary of China Merchants Bank Co.,Ltd. The company has established major business lines including asset management products and dedicated wealth management business with extensive investment in Asia-Pacific and global secondary markets, cross-border business (QFII, etc.), project direct investment business (equity, debt, etc.), and investment advisory business. The product lines cover a series of funds such as equity, bond, FOF, quantitative investments, and PE, as well as various customized products for special accounts.